Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder in children and adolescents. MannKind ...